The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Legislators who favor the liability protection for Bayer say lawsuits alleging the herbicide Roundup causes cancer would hurt the agriculture industry facing increased costs. Opponents demand ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with lenalidomide ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

"It's a little overwhelming, but everyone's been so amazing and supportive and it makes me feel really great," junior Taylor LaRoche said, who was diagnosed with Hodgkin's Lymphoma last Christmas Eve.

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

The diagnosis of spinal cord lymphoma is often delayed due to the high risks associated with a spinal cord biopsy, the rarity of the disease, and the lack of specificity of its clinicoradiological ...